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ABSTRACT: Early detection of cancer plays a crucial role in disease
prognosis. It requires the recognition and quantiﬁcation of low
amounts of speciﬁc molecular biomarkers, either free or transported
inside nanovesicles, through the development of novel sensitive
diagnostic technologies. In this context, we have developed a
nanoarray platform for the noninvasive quantiﬁcation of cancer
biomarkers circulating in the bloodstream. The assay is based on
molecular manipulation to create functional spots of surface-
immobilized binders and diﬀerential topography measurements. It
is label-free and requires just a single binder per antigen, and when it
is implemented with ﬂuorescence labeling/readout, it can be used for
epitope mapping. As a benchmark, we focused on the plasma release
of Her2 extracellular domain (ECD), a proposed biomarker for the
progression of Her2-positive tumors and response to anticancer therapies. By employing robust, easily engineered camelid
nanobodies as binders, we measured ECD-Her2 concentrations in the range of the actual clinical cutoﬀ value for Her2-positive
breast cancer. The speciﬁcity for Her2 detection was preserved when it was measured in parallel with other potential biomarkers,
demonstrating a forthcoming implementation of this approach for multiplexing analysis. Prospectively, this nanorarray platform
may be customized to allow for the detection of promising new classes of circulating biomarkers, such as exosomes and
microvesicles.
■ INTRODUCTION
The past decade has witnessed the development of diagnostic
devices based on diverse physical principles for the highly
sensitive, noninvasive, and fast detection of disease-related
biomolecules.1−3 In this assorted framework, nanotechnological
breakthroughs in terms of integration and miniaturization of
the various bioassays2 have pushed beyond the limitations of
conventional approaches. Notable examples are miniaturized
electrochemical and surface plasmon resonance (SPR)-based
sensors, functional nanoparticles, and protein/DNA nanoarrays
that can oﬀer enhanced precision and signiﬁcantly faster
measurements than those achieved with current technolo-
gies.4−7 Miniaturized, integrated, and multiplexed strategies
would be of particular utility when moving in the direction of
noninvasive “liquid biopsy”, i.e., the detection of reliable
biomarkers (proteins, nucleic acids, nano- and microvesicles,
and circulating cells) directly in the bloodstream of patients to
monitor early stage tumor occurrence as well as its evolution
during therapy.
We propose here an atomic force microscopy (AFM)-based
miniaturized bioaﬃnity test for the quantiﬁcation of blood-
circulating protein biomarkers. This approach capitalizes on
other studies performed by our group1,8,9 and is based on the
precise conﬁnement of high-aﬃnity antigen-binding molecules
on a surface by means of AFM nanografting of single-stranded
DNA (ssDNA) and DNA-directed immobilization (DDI) of
conjugated binders, following the scheme in Figure 1.
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In particular, we focused our attention on the detection of
the blood-released portion of human epidermal growth factor
receptor 2 (Her2). Her2 is a member of the epithelial growth
factor receptor (EGFR/ErbB) family, which is involved in
many biological processes, such as signal transduction,
regulation of cell adhesion, regulation of transcription, positive
regulation of cell growth/proliferation, and negative regulation
of apoptosis.10 It is normally expressed at low levels in the
epithelial cells of many tissues, whereas gene ampliﬁcation and
overexpression of Her2 are observed in many types of cancer,
such as breast, lung, ovarian, and gastric.11 In breast cancer, this
ampliﬁcation deﬁnes a subtype of cancer (Her2-positive
cancers) with a unique gene signature that is maintained
during progression.12,13 The ability to reveal this “signature” at
extremely low concentrations may be used for early stage
cancer detection and/or to monitor and follow cancer
progression to tune personalized drug treatments.
The increase in membrane concentration (crowding) of
Her2 induced by receptor overexpression might be the leading
cause of aberrant, ligand-independent homodimerization or
heterodimerization with other ErbB receptors, which in turn
causes proteolytic cleavage of the Her2 extracellular domain
(ECD), known as shedding,14 and downstream signaling
activation.15,16 Anti-Her2-positive cancer therapies based on
humanized antibodies, such as trastuzumab and pertuzumab,
are focused on blocking Her2 dimerization and/or shedding
and/or Her2-dependent signals.17 Although it is strongly
discussed in the clinic, the lack of suitable technologies to
detect circulating ECD-Her2 prevents this molecule from being
considered a proper biomarker at present. A precise
quantiﬁcation of the level of ECD-Her2 released and circulating
freely in the bloodstream or as nanovesicle (exosome) cargo
might boost the ability to detect Her2-positive tumors early in
their development after diagnosis and allow tumor response to
Her2-targeted therapy to be monitored.
So far, enzyme-linked immunosorbent assays (ELISAs)
constitute the only FDA-approved clinical method to evaluate
the amount of circulating ECD-Her2 in the serum of patients
with both primary breast cancer and metastatic disease16 and to
monitor their response to therapeutic treatments.18,19 With this
method, ECD-Her2 has been found in 30% of primary breast
tumors and 50% of metastatic ones.20 However, ELISA bears
some limitations, such as the use of expensive labels and the
need for multiple antibodies for the same analyte, in addition to
the diﬃculty of implementing it in multiplexing analysis. This
last point is crucial, given that other soluble forms of ECD-
Her2 could derive from alternative splicing (e.g., herstatin and
p100). The ability to detect multiple biomarkers is strongly
required to unequivocally correlate these quantitative measure-
ments with tumor status and progression.
In this speciﬁc context, we propose to exploit the full
potential of our innovative nanoarray platforms. To move
toward clinical applications, we pushed their sensitivity for
antigen detection, exploiting diﬀerent binders with diﬀerent
aﬃnity/recognition epitopes. With respect to ELISA, AFM
nanoarrays enable multiplexing, require no labeling, and entail a
single type of binder for analysis. In particular, we used two
diﬀerent mouse IgG monoclonal antibodies (Abs) selected for
their high binding aﬃnity to regions outside the epitope
recognized by trastuzumab, which makes them suitable for
monitoring the disease during therapeutic drug treatment.
Then, we explored alternative binders such as high-aﬃnity
single-domain nanobodies (VHH) (12−15 kDa) selected to
bind epitopes in the Her2 hinge region.21,22 With respect to
antibodies, nanobodies are more stable and can be easily
engineered with speciﬁc tags and fusion partners to meet
diagnostics needs, contributing to an overall reduction in the
cost of the device.22,23 Moreover, nanobodies can be selected to
avoid cross-reaction with the human anti-mouse antibodies
(HAMA) that are present in human serum and could limit the
eﬃcacy of antigen quantiﬁcation.
Nanoarray detection performance was tested for a broad
range of Her2 concentrations in buﬀer and then in standardized
human serum. To demonstrate the multiplexing capabilities of
this approach, we evaluated the simultaneous recognition of
Her2 and urokinase plasminogen activator (uPA), which
participate in cell migration, angiogenesis, embryogenesis,
tumor cell dissemination, and metastasis in many tumors.
Increased levels of uPA have been reported in primary breast
cancer patients and correlate with tumor aggressiveness.24 To
prove the reliability to our method, we validated the AFM
nanoarray with SPR and ﬂuorescence microscopy (FM)
measurements. We also used diﬀerent combinations of available
Her2 binders to build a sandwich assay to identify, via
combined AFM and FM measurements, the epitope involved in
the speciﬁc binding interaction.
■ RESULTS
Her2 Detection with MGR2 and MGR3 Antibodies.
Initially, we used two mouse monoclonal antibodies, MGR2
and MGR3, for to set up and validate the nanoarray. Both
antibodies recognize ECD-Her2 with high speciﬁcity and have
been thoroughly characterized in immunoprecipitation experi-
ments and by immunohistochemistry using Her2-overexpress-
Figure 1. Schematic representation of the DDI strategy to immobilize antibodies on a microsized DNA-based biosensor.
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ing cell lines.25,26 A competitive immunoassay as an epitope
binning experiment demonstrated that MGR2 and MGR3 bind
to independent epitopes on the ECD-Her2 protein surface,
which in turn diﬀer from the epitope bound by trastuzumab.25
Toward the realization of the nanoassay, we ﬁrst conjugated
the two antibodies with ssDNA by means of a commercial click
chemistry kit that exploits amine groups available on the surface
of an antibody to covalently anchor the DNA. Such a
bioconjugation method is a highly eﬃcient (>80% of the
protein is conjugated), three-step procedure in which both
protein and DNA are ﬁrst modiﬁed with speciﬁc chemical
groups that “click” together. The produced conjugate is
extremely stable, and the degree of DNA−protein functional-
ization is then quantiﬁable by UV spectrophotometry. To avoid
multiple strands attached to a single Ab, sterically limiting the
binding aﬃnity to the target, we optimized the original
conjugation protocol, obtaining two−three strands per protein,
on average, and never more than four.
For nanoscale functionalization, we combined DNA nano-
grafting, ﬁne-tuning the process to optimize the density of
patterned biomolecules,8 and the immobilization of semi-
synthetic Abs−DNA conjugates through DDI with high
eﬃciency, site-selectivity, and reversibility.27,28 We then
capitalized on AFM topographic imaging to visualize any
change in the surface topography of the nanopatches occurring
upon interaction with the antigen, with subnanometric
resolution, and to quantify the number of biorecognition
events, as successfully demonstrated in previous work published
by our group.1,8,27,29,30 The height of the patch is measured at
each step of the fabrication (i.e., ssDNA nanografting, DDI of
Abs−DNA conjugates, antigen binding) with respect to the
surrounding self-assembled monolayer (SAM) of biorepellent
alkanethiols through topographic AFM images. The unchanged
roughness over the SAM throughout the entire process is an
indication of SAM antifouling action.31−33
Figure 2. ECD-Her2 nanoarray detection by MGR2 (A−C) and MGR3 (D−F) Abs. (A, D) AFM images across the nanopatches after DNA
immobilization, antibody loading via DDI, and binding of the antigen. (B, E) Relative topographic line proﬁles from the AFM images in panels A and
D (light blue, DNA nanografting; red, Ab-conjugate immobilization via DDI; green, 10 nM ECD-Her2 binding). (C, F) Mean and SD values of the
patch heights measured from the line proﬁles across the nanopatches, which correspond to the colored areas in images A and D at each step of the
experiment.
Figure 3. ECD-Her2 binding curves for MGR2−DNA (left) and MGR3−DNA (right) conjugates immobilized on the nanoarray. Average values of
the variation in height (Δh) detected on the nanopatches (n = 4) are plotted versus ECD-Her2 concentration. Data were analyzed using the Hill
equation with sigmoidal ﬁtting, and KD values were determined.
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The binding of 10 nM ECD-Her2 over MGR2 and MGR3
antibody nanostructures is reported in Figure 2. Images of the
nanopatches (Figure 2A,D) show that the height increases at
each step of the assay until antigen binding (the brighter the
color, the higher the nanoassembly height versus the reference
SAM). Relative height variations are visualized that show the
topographic line proﬁles (Figure 2B,E) and are reported as
absolute values (Figure 2C,F).
In both cases, the average height of the ssDNA nanopatches
(Figure 2B,E, blue lines) is close to 3.0 nm. This experimental
value is in agreement with the expected output due to the “low-
density” nanografting conditions (S/A = 0.3−0.6), in which the
vertically standing thiolated DNA molecules are below the
highest packing limit (around 5 nm34) and are therefore not
fully vertically stretched by repulsive electrostatic forces.35 This
DNA density has been previously identiﬁed as the optimal one
to accommodate the steric hindrance of the subsequently
immobilized antibodies and to make their binding site easily
accessible to the analyte in solution (Figure S4).
Immobilization of the DNA−antibody conjugate provides a
height increase of roughly 4−5 nm (Figure 2B,E, red lines).
The further increase in the height after incubation with ECD-
Her2 (Figure 2B,E, green lines) clearly indicates the eﬃcient
antibody-dependent capture of the antigen.
Next, the nanodevice was assessed for its ability to
quantitatively measure the target. We calculated the aﬃnity
calibration curve for both MGR2 and MGR3, with the
assumption that the variation in height across the nanopatches
is proportional to the amount of analyte bound to the ligand.
Variations in height were plotted versus ECD-Her2 concen-
tration (ranging from 200 pM to 100 nM in the case of MGR2
and from 1 to 300 nM in the case of MGR3; Figure 3).
The sigmoidal distribution of data is in agreement with the
saturable binding isotherm for a receptor−ligand binding
equilibrium and was ﬁtted with the Hill equation,36 obtaining
a dissociation constant KD in the low nanomolar range for both
MGR2 (KD = 3.3 ± 0.9 nM) and MGR3 (KD = 17.0 ± 10.7
nM). From Figure 3, we determined a limit of blank (LoB)
value of about 1 nM for the higher aﬃnity MGR2 and 3 nM for
MGR3.
To validate the nanoarray results, we set up a standard ELISA
assay in which diﬀerent concentrations of Abs were added to
ECD-Her2-coated wells (Figure S6). The dissociation constant
values found with this assay (MGR2: KD = 2.3 ± 1.3 nM;
MGR3: KD = 23.0 ± 6.2 nM) were in very good agreement
with those found with the nanoarray (conﬁdence level (CL) =
0.74 and 0.69, respectively). SPR experiments were also
performed to evaluate whether functionalization aﬀects an
antibody’s aﬃnity for its antigen. The immobilization
conditions used on the nanoarray were reproduced by attaching
biotinylated ssDNAs to a streptavidin-modiﬁed dextran matrix.
The Ab conjugated with the complementary DNA was then
linked by DDI to the matrix, and then the ECD-Her2 analyte
was ﬂuxed. We tested the conjugate with the higher aﬃnity Ab,
MGR2, and found that the KD was in the low nanomolar range
(17.1 ± 1.1). The diﬀerent experimental setup explains the
much higher KD value obtained with SPR with respect to the
nanoarray and ELISA; nonetheless, the low nanomolar KD
value conﬁrms that eﬃcient antigen recognition is enabled in a
nanoarray-like conﬁguration.
Her2 Detection with EM1 Nanobody. As an alternative
to conventional antibodies, we exploited camelid nanobodies,
which are recombinant molecules that can be easily engineered
at precise and unique residues to avoid multiple and
heterogeneous labeling and loss of activity. Moreover, due to
their reduced dimensions, nanobodies can be used to prepare
functional surfaces with higher ligand densities compared to
that with conventional antibodies, which simultaneously
increases the active detection surface and avoids steric
hindrance. In particular, we recently showed the advantage of
producing nanobodies specialized for ECD-Her2 biorecogni-
tion with a free C-terminal cysteine available for single-point
maleimide functionalization.37 This approach enables function-
alization using residues not involved in the Ab paratope, which
consequently prevents modiﬁcations of the Ab−antigen
binding features. The llama nanobody EM1 was selected in
vitro from a naiv̈e library38 using the same strategy reported in
Djender et al.39 It binds to an ECD-Her2 epitope close to the
one recognized by trastuzumab. EM1 was expressed with a free
C-terminal cysteine and covalently linked with a maleimide−
ssDNA construct. We ﬁrst measured the binding properties of
1:1 EM1−ssDNA conjugates by SPR, ﬁnding a KD of 3.4 ± 0.3
nM. We then proceeded with nanobody−DNA conjugate
nanoscale immobilization on a gold surface with the same DDI
approach used for the MGR2 and MGR3 antibodies.
The ﬁrst two preliminary steps (grafting ssDNA and
hybridizing the DNA−nanobody conjugate) were optimized
according to the small dimensions (2 × 2 × 3 nm3; ∼15 kDa)
of VHHs. Notably, the density of grafted ssDNA sequences has
a great impact on the hybridization of the conjugate and
consequently on the detection of Her2. Whereas low DNA
densities are needed to avoid steric hindrance eﬀects in the case
Figure 4. Detection of ECD-Her2 on the nanoarray. Images of nanopatches on the gold surface (A) and their topographical proﬁles (B). (C) Mean
and SD values of the height measured across the nanopatches at each step of the experiment (light blue, grafting of ssDNA; red, hybridization of
VHH−DNA conjugate; and green, 1 nM ECD-Her2 incubation).
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of full antibodies, voids should not be left in the nanografted
DNA SAM for nanobodies; the nanobody itself could hide in
such voids, becoming unavailable to interact with the analyte.
On the contrary, at high DNA density, the nanostructures are
well packed and the binder stands up over the surface DNA
layer in the right conﬁguration. This explains why, as shown in
Figure S5, the conditions for high-performance target detection
were reached only at high density. Tuning the DNA density
and DDI conditions, depending on the dimensions and the
speciﬁc characteristics of the binder, to optimize detection
performance in the immunoassay is a unique feature of AFM
nanografting.
Having optimized the immobilization conditions, we
performed ECD-Her2 detection with EM1 conjugate nano-
structures, following the same experimental procedure as that
used for the Abs (ssDNA grafting, DDI-driven conjugate
immobilization, and target binding). As a representative case,
we report the results related to the detection of 1 nM ECD-
Her2 (Figure 4).
The measured height of the “high-density” grafted ssDNA is
4.5 ± 0.2 nm, a value that describes the highest packing
nanopattern in which the thiolated DNA molecules stand
vertically.34
As provided for the MGR2 and MGR3 Abs, we determined
the EM1−ECD-Her2 binding aﬃnity curve with diﬀerent
analyte concentrations ranging from 200 pM to 10 nM (Figure
5).
We ﬁtted data with the Hill equation in this case as well,
determining a dissociation constant of KD = 1.8 ± 0.6 nM,
which is lower than that for MGR2. The S/N ratio improves
substantially upon moving from antibody to nanobody binders,
probably because the higher density DNA layer underneath
increases the mechanical robustness of the device; the read-out,
in fact, is based on a mechanical probe, which still reﬂects the
mechanical resistance of the surface even though it is operated
at minimum force. Overall, the limit of sensitivity (LoB)
decreases to about 200 pM, pushing the nanoarray’s sensitivity
to a level comparable to the cutoﬀ value of 15 ng/mL that is
commonly used in the clinic for Her2-positive breast cancer
assessment.40,41
Her2 Detection in Standardized Human Serum. As an
intermediate step toward using this approach for detection in
blood serum samples, we tested the capability of the nanoarray
to recognize the target of interest in human serum. We chose to
work with standardized human serum ﬁrst, which mimics the
serum of human patients in terms of protein content (IgG
antibody and albumin). First, we assessed nonspeciﬁc protein
binding to the functionalized patches and/or to the
surrounding thiol carpet. As shown in Figure 6A, we observed
a negligible increase in the patch height (about 0.2 ± 0.4 nm)
upon moving from PBS to standardized human serum. Also,
the roughness of the biorepellent SAM carpet did not change
signiﬁcantly (rms = 0.23 and 0.25 nm before and after serum
incubation, respectively). Instead, upon addition of 1 nM ECD-
Her2 to the serum, we observed a relevant patch height
increase of 1.3 nm (Figure 6A). This value is the same as the
diﬀerential height increase (Δh) extracted for an ECD-Her2
concentration of 1 nM from the calibration curve obtained with
the recombinant protein in buﬀer solution. This proves that our
nanoarray is capable of ﬁltering the background noise of a
biological sample and recognizing a speciﬁc biomarker of
interest.
Multiplexed Detection. To further challenge the capability
of the nanoarray and to prove its validity for use in clinical
practice, we performed a preliminary multiplex analysis, testing
the simultaneous detection of ECD-Her2 and uPA, another
relevant breast cancer biomarker. As shown in Figure 7, we
grafted ssDNA SAM nanopatches of two diﬀerent DNA
sequences (SH-cF9 and SH-cF5) in serial order, enabling the
immobilization of two binders (VHH EM1 and αuPA Ab)
each of them conjugated by means of its complementary
ssDNA (F9 and F5)speciﬁc for independent antigens. We
then performed a selective detection of the diﬀerent targets,
adding each of them in sequence to the solution.
The proﬁle across the grafted SH-cF5 and SH-cF9 ssDNA
patches was acquired ﬁrst (black proﬁles in Figure 7B, left and
right, respectively). Then, we inserted the VHH-F9 conjugate
(red curves in Figure 7B), observing that only the patches on
the right show a height increase, whereas across the patches on
the left, the red proﬁle almost overlaps with the previously
acquired black curve. This demonstrated the speciﬁcity of the
DDI process. Similarly, after adding the uPA Ab-F5 (blue
curves in Figure 7B), we see a height increase corresponding to
the cF5 patches (panel B, left) but not corresponding to the
cF9 patches (panel B, right). Finally, the loading of uPA was
sensitively measurable only across the uPA Ab-F5 patches
(green proﬁles in Figure 7B), and the last incubation with
ECD-Her2 was detectable only across the VHH-F9 patches
(yellow proﬁles in Figure 7B), completing the demonstration of
the speciﬁcity of our nanoarray.
The unchanged roughness of the thiol SAM carpet at each
step further indicated that nonspeciﬁc binding over the surface
did not occur, proving again the validity of the TOEG6 SAM
carpet as a reference for height measurements. Two diﬀerent
antigens were incubated over the surface at the same
concentration (20 nM); the diﬀerent Δh values (uPA = 2.7
nm; ECD-Her2 = 4 nm) observed can be explained by the
diﬀerent dimensions of the two proteins (53 and 72 kDa,
respectively).
The high selectivity of the binding of the two Ab−Ag pairs
working in parallel is a promising result that indicates the
possibility of implementing the multiplexing nanoarray under
real conditions.
Figure 5. Binding curve of ECD-Her2 and EM1 nanobody conjugate
immobilized on the nanoarray surface. Average changes in height (Δ
height) values on nanopatches (n = 8) are plotted versus ECD-Her2
concentration; the data were analyzed with the Hill using equation
sigmoidal ﬁtting, and KD values were determined.
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Fluorescence Experiments. So far, we have demonstrated
that our nanoarrays work in a sensitive and antigen-speciﬁc
manner, with clear advantages over ELISA platforms because
the nanoarrays use small volumes and, more importantly,
require only one binder per antigen. To perform an additional
validation of our nanoarray, we compared the single protein
Figure 6. ECD-Her2 detection in standardized human serum. (A) Nanopatch height variation (n = 8) on the nanobody-immobilized nanoarray
incubated with standardized human serum with or without 1 nM ECD-Her2. (B) Extrapolation of the height increase expected from the nanobody-
based calibration curve.
Figure 7. Multiplex detection of two diﬀerent biomarkers (ECD-Her2 and uPA) on the same surface. (A) Schematic of DDI immobilization of
binders on the DNA-based biosensor and subsequent detection of the antigens. Height variations of the two separated sets of DNA nanopatch SAMs
(cF5 and cF9) after each biomolecule incubation step (in the following sequential order: VHH EM1-F9 conjugate, αuPA Ab-F5; ECD-Her2 antigen,
and uPA antigen) are visualized by topographic proﬁles (B) and histograms (C); mean and SD height values (n = 4) are reported in the tables.
Columns where no binding was expected (and therefore no height increase) are gray.
ACS Omega Article
DOI: 10.1021/acsomega.7b00284
ACS Omega 2017, 2, 2618−2629
2623
binder topographic measurement approach and the conven-
tional nanoarray-based sandwich approach with a ﬂuorescent
readout. The goal is to label the nanostructures with a
ﬂuorescent molecule as unequivocal proof of the presence of
the target bound on the surface.
Moreover, we also aim to demonstrate that a ﬂuorescence-
integrated sandwich nanoarray allows epitope binning of the
binders to be performed by analyzing the pattern of
simultaneous or competitive action of diﬀerent pairs of binders.
As a ﬁrst approach, we used an “indirect” sandwich
conﬁguration (Figure 8A), more similar to classical ELISA
setups. We ﬁrst immobilized the Abs on the surface, and after
ECD-Her2 capture, we added another Ab speciﬁc for another
independent epitope. The ﬂuorescent signal was obtained using
a ﬂuorescently labeled secondary α-mouse Ab. From Figure 8,
it can be seen that the match between topographic and
ﬂuorescence data in this indirect nanosandwich approach is
very good.
The successive incubation steps were as follows: (i) ssDNA,
(ii) trastuzumab−DNA conjugates, (iii) ECD-Her2, (iv)
MGR2, and (v) secondary α-mouse ﬂuorescent Ab. Notably,
we conﬁrmed, by means of ﬂuorescence measurements, that
even a low topographic height increase (0.2−0.5 nm)
corresponds to a measurable ﬂuorescent signal, validating the
occurrence of binding of target at very low concentrations (200
pM). Moreover, as demonstrated by the values reported in the
tables and in the AFM−ﬂuorescence correlation graph in
Figure 8c, the ﬂuorescence signal scales linearly with the
topographic signal and with the density of ssDNA grafted on
the surface, which in turn correlates with the binder density and
therefore the total amount of captured target molecules. This
not only validates the quantitative analysis performed through
topographic measurements across the nanopatches of the
nanoarray but also conﬁrms that our single-binder assay retains
all the beneﬁts of ELISA with the advantages of simplicity,
lower cost, and greater eﬃciency.
In addition, the ﬂuorescence-integrated sandwich-nanoarray
setup might be useful to obtain important information about
protein epitopes recognized by diﬀerent binders. For this, we
used the same indirect approach described above as well as a
simpliﬁed “direct” sandwich approach by exploiting the easy
functionalization of the VHH EM1. As the ﬁrst binder, we used
a mouse/humanized Ab, whereas the second one was GFP-
conjugated VHH. The two conﬁgurations are reported in
Figure 9 together with ﬂuorescence images relative to diﬀerent
combinations of binders in the sandwich.
We noticed that the ﬂuorescence signal coming from the
secondary antibody is generally sharper compared to the GFP
ﬂuorescent signal on the VHH. This could be related to the
diﬀerent ﬂuorescence quantum yield, to the ampliﬁcation eﬀect
due to the secondary Ab, or to the diﬀerent dimensions of the
two systems, with VHH being 5 times shorter than the Abs and
therefore closer to the gold surface, which could partially
quench the ﬂuorescence signal.
With this in mind, we used the VHH-related direct
conﬁguration (Figure 9D−F) to test its relative epitope for
Figure 8. Fluorescent visualization of ECD-Her2 captured by the nanoarray. (A) Schematic of the molecular nanoassembly on a gold surface
together with AFM images of the patches at each step of the incubation (sequentially: ssDNA, trastuzumab−DNA conjugate, 200 pM ECD-Her2,
and MGR2) at diﬀerent densities of grafted ssDNA (indicated with diﬀerent colors, see the text). Scale bar 2 μm. (B) Fluorescent image of the
patches described in (A) after incubation with anti-mouse Ab labeled with Alexa488 ﬂuorophore. Scale bar 2 μm. (C) Height increase values
recorded with AFM topographic analysis after each incubation step on the patches and ﬂuorescence intensity values measured as pixel counts. The
plot shows ﬂuorescence−AFM topography correlation (number of independent patches: four for each grafted ssDNA density).
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ECD-Her2 recognition. While a ﬂuorescence signal was visible
when it was coupled to MGR2 (Figure 9D) and pertuzumab
(Figure 9F), no ﬂuorescence was observable when it was
coupled to trastuzumab (Figure 9E). This fact indicated that
VHH EM1 and trastuzumab bind on close/overlapping
epitopes and that these are totally independent from the one
recognized by pertuzumab, as reported in the literature.42
Concerning MGR2, whose epitope has not been mapped yet,
our preliminary experiments indicate simultaneous binding with
VHH; therefore, MGR2 does not exhibit cross-reactivity with
VHH. Translating the results of Figure 9D,E, we conclude that
MGR2 and trastuzumab recognize diﬀerent epitopes. This was
conﬁrmed by results obtained with the indirect conﬁguration
(Figure 9C), where we observed the presence of the
ﬂuorescence signal corresponding to the concomitant binding
of MGR2 and trastuzumab, proving that the MGR2-function-
alized nanoarray is suitable for monitoring a response to
therapeutic treatment with this humanized Ab.
With the indirect assay, we also conﬁrmed the simultaneous
binding of MGR2 and MGR3 (Figure 9A). The data in Figure
9B relative to the sandwich binding of MGR2 and VHH are
apparently in contradiction with the data in Figure 9D, in which
the same binders are used but in reverse order. This could be
explained by the fact that, due to the small dimensions of the
nanobody, the accessibility of the Ab to the analyte would be
limited as a consequence of its proximity to the surface.
Combining the evidence from both the direct and indirect
conﬁgurations with these two binders, we can assume that the
binding sites of VHH EM1 and MGR2 on ECD-Her2 are most
likely very close. These experiments demonstrate that nano-
grafting-based nanoarrays, beyond their potential as a detection
tool, can serve as an alternative approach, complementary to
more conventional methods, for identifying the molecular
determinants of antibody−antigen recognition.
■ DISCUSSION
The use of miniaturized devices in liquid biopsy for cancer
biomarker detection and therapy monitoring will ultimately
improve the outcome of early diagnosis and tumor treatment.
Here, we employed a nanoarray based on AFM nano-
lithography and a topographic readout for the detection of
cancer-relevant biomarkers circulating in the bloodstream. We
focused on the detection of ECD-Her2, optimizing the choice
of binders to increase the detection sensitivity and even using it
in multiplexing with uPA, to move toward biomolecular
footprinting of the disease.
In particular, we demonstrated that nanoarrays employing
panning-selected camelid nanobodies can detect ECD-Her2 at
less than 200 pM, which corresponds to the cutoﬀ value of 15
ng/mL currently used in the clinic to discriminate between a
healthy and pathological status. We showed that the high
aﬃnity of nanobodies can be fully exploited by tuning the
surface density of the binders: At variance with classical
antibodies, for which steric hindrance can promote anticooper-
ativity of adjacent binders, higher probe densities can be used
for smaller binders and indeed help to improve the overall
sensitivity of target identiﬁcation.
We expect that the introduction and optimization of suitable
linkers and in silico engineering platforms exploiting novel
mixed computational−experimental protocols for boosting the
aﬃnity for a cognate antigen43 will substantially improve the
use of nanobodies as capture molecules and further decrease
the detection limit to the hundreds of femtomolar/low
picomolar range. In this direction, we plan to identify in silico
customized VHHs for speciﬁc (nonimmunogenic) epitopes of
Figure 9. Fluorescence images obtained with diﬀerent combinations in the Ab/VHH “sandwich” assay. For images related to the indirect
conﬁguration (A−C), the ﬁrst Ab of the sandwich is indicated in purple and the second is in blue; for the direct conﬁguration (D−F), the ﬁrst Ab of
the sandwich is indicated in purple. Next to each ﬂuorescence image is reported the schematic representation of the position of the patches (violet
squares). Scale bar 2 μm.
ACS Omega Article
DOI: 10.1021/acsomega.7b00284
ACS Omega 2017, 2, 2618−2629
2625
Her2 fragments by means of computational design42 and/or
high-aﬃnity peptides for chosen epitopes of target proteins by
stochastically exploring their sequence and structure space.
In conclusion, we demonstrated that this simple assay has the
required sensitivity to be operated in the clinic, allowing
detection in small volumes of complex matrices and enabling
continuous noninvasive monitoring of therapy from single
blood droplets. Moreover, at variance with ELISA, our assay
requires a single binder for each biomarker and is label-free,
avoiding false results connected to ﬂuorescence interference
susceptibility and tremendously reducing diagnostic costs while
maintaining high biorecognition speciﬁcity and fast readout. On
the basis of the achieved results, we put forward the idea of
implementing a simpliﬁed, automated, cantilever-based readout
machine in the clinic for antigen quantiﬁcation purposes.1
When coupled with frequent, noninvasive monitoring in
single blood droplets, our method might then have a crucial
impact on therapeutic drug monitoring, simultaneously
proﬁling multiple circulating biomarkers and accounting for
the time evolution of the cancer genome and consequent
resistance to drug treatment. Similar nanoscale platforms can be
generated to anchor selected populations of exosomes, via the
binding of a speciﬁc transmembrane protein, and to character-
ize them in terms of other membrane protein components. All
of these features heighten the signiﬁcance of our nanoarray as
an attractive platform for personalized cancer diagnostic
applications.
Finally, the same nanoarray can serve as a platform for
epitope binning. This, combined with ﬂuorescent assays in
living cell membranes for colocalization of diﬀerent receptors,
will help to understand the speciﬁc functions enabled by
selective binding, paving the way to the modular design of
synthetic receptors.
■ METHODS
DNA. ssDNA sequences (SH-cF9: SH-(CH2)6-5′-CTTCA-
CGATTGCCACTTTCCAC-3′, F9: NH2-(CH2)6-5′-GTGGA-
AAGTGGCAATCGTGAAG-3′, SH-cF5: SH-(CH2)6-5′-
CTTATCGCTTTATGACCGGACC-3′, F5: NH2-(CH2)6-5′-
GGTCCGGTCATAAAGCGATAA-3′) were from Biomers
GmbH Ulm, Germany.
Antibodies and Nanobodies. Monoclonal mouse anti-
bodies MGR2 and MGR325,26 were produced at Fondazione
IRCCS Istituto Nazionale dei Tumori, Milan. These Abs have
been tested in IHC, immuno precipitation (CoIP), and
immunoblot assays.25,26
Commercial monoclonal human antibodies trastuzumab and
pertuzumab were from Genentech.
Commercial monoclonal αuPA antibody was from MyBio-
Source.
Single-domain antibodies (VHH) were isolated and
produced at the University of Nova Gorica as described
previously using a naiv̈e nanobody library,38 a diﬀerential
panning approach on whole cells, and the cytoplasmic
expression of the nanobodies in the presence of sulfhydryl
oxidase.39
Proteins and Standardized Serum. Recombinant human
ECD-Her2 and uPA were from ACRO Biosystems.
Standardized human serum was from Biseko (Biotest).
Conjugates Production. Antibodies. Conjugation of the
MGR2, MGR3, trastuzumab, and pertuzumab antibodies with
ssDNA sequence F9 and the αuPA antibody with F5 was
performed using a click chemistry reaction using the
commercial three-step SoluLink protein−oligo conjugation kit
(Figure S1).
Protein Modiﬁcation. Antibodies at a concentration of 2.5−
4.0 mg/mL were buﬀer exchanged into modiﬁcation buﬀer
(100 mM phosphate, 150 mM NaCl, pH 8.0) usingZeba desalt
spin columns (Pierce Chemical) before adding 10−20 mol
equiv of HyNic/mol antibody. The reaction was carried out at
room temperature for 1.5 h, and the HyNic-modiﬁed antibody
was desalted into conjugation buﬀer (100 mM phosphate, 150
mM NaCl, pH 6.0).
Oligonucleotide Modiﬁcation. The oligonucleotide was
desalted into nuclease-free water using a 5K MWCO VivaSpin
diaﬁltration apparatus, and the OD/μL concentration at 260
nm was adjusted to 0.2−0.5 OD/μL. A volume containing 20
equiv S-4FB was added to the oligonucleotide solution and
incubated at room temperature for 2 h. The 4FB-modiﬁed
oligonucleotide was equilibrated into conjugation buﬀer (100
mM phosphate, 150 mM NaCl, pH 6.0).
Protein−Oligo Conjugation. Volumes of the antibody and
oligonucleotide were mixed. One-tenth of the volume of 10×
TurboLink catalyst buﬀer was added to the conjugation
solution, and the reaction was carried out at room temperature
for 2 h; the amount of the two components used in this step is
strictly related to the concentration and the molar substitution
ratio (MSR) of both HyNic-modiﬁed protein and 4FB-
modiﬁed oligonucleotide obtained in the previous steps.
The conjugation reaction was visualized spectrophotometri-
cally by determining the absorbance at A354 due to the
formation of the chromophoric conjugate bond. The reaction
solution was exchanged with PBS using Zeba columns.
Nanobody. The conjugation of nanobody EM1 with ssDNA
sequence F9 was performed by a maleimide reaction (Figure
S2): the nanobody, containing a free cysteine at its C-terminus,
was diluted to a concentration of 100 μM in Hepes 10 mM pH
7.4 buﬀer and kept reduced by the addition of TCEP in a 10-
fold molar excess for 20 min at room temperature. F9-
maleimide was dissolved in TE buﬀer (Tris 10 mM, EDTA 1
mM) pH 8.0 and then added to the nanobody with a
ssDNA:protein molar ratio of 10:1 (250:25 μM:μM). After 2 h
at room temperature, the modiﬁed nanobody was separated
from the reactants and reaction byproducts using a G-25
Illustra microspin column (GE Healthcare Life Science).
Surface Plasmon Resonance. Biacore T100 and Biacore
2000 SPR instruments were used at a constant temperature of
25 °C.
As shown in Figure S3, a biotinylated cF9 sequence (cF9-
biotin, 2 μM in PBS buﬀer) was immobilized over the Biacore
SA gold chip surface. A continuous ﬂow (5 μL/min) of PBS
buﬀer (running buﬀer) was maintained during all experiments.
The immobilization through streptavidin−biotin binding was
stopped after reaching a binding level of ∼1200 RU,
corresponding to an amount of ssDNA on the surface that
ensured an eﬃcient attachment of the molecules in the
following steps of the experiment. The surface was rinsed twice
with a 1 min pulse of 50 mM NaOH solution to remove
unbound cF9-biotin.44 The hybridization was carried out by
incubation with the conjugates at 100 μM in TE buﬀer with 1
M NaCl until reaching a binding level of ∼1200 RU. The
binding aﬃnity of ECD-Her2 was evaluated by injecting two
diﬀerent concentrations of the protein in running buﬀer at a
ﬂow rate of 30 μL/min for 3 min (association phase) and
afterward ﬂushing with running buﬀer for 10 min (dissociation
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phase). Since the dissociation phase allows complete detach-
ment of the protein, no regeneration procedure was required.
Binding aﬃnity parameters were determined using the 1:1
Langmuir model in the BIAevaluation 3.1 software.
AFM Measurements. The tip-assisted AFM-based nano-
lithography used to fabricate DNA nanoarrays and all high-
resolution topographic measurements were performed using an
XE-100 (Park-Systems) with a custom liquid cell at room
temperature. First, a biorepellent SAM of top oligo(ethylene
glycol)-terminated alkylthiols (TOEG6: HS-(CH2)11-
(OCH2CH2)6-OH, Sigma-Aldrich) was prepared on ultraﬂat
stripped gold surfaces following a modiﬁed version of the
Ulman procedure.45 A gold sample was soaked in a 300 μM
solution of TOEG6 in ethanol for about 24 h. Then, it was
rinsed with distilled water and ethanol, dried with a gentle
stream of nitrogen, and ﬁnally glued inside the AFM liquid cell.
Multiple nanografting assembled monolayers of thiol-
modiﬁed ssDNA SH-cF9 were prepared by serial AFM-based
nanografting inside the TOEG6 SAM.
1,8,27,29,46 An AFM tip
with suﬃcient rigidity (MikroMasch NSC 19/no Al, spring
constant 0.6 nN nm−1) was operated at high load (set point/
force ≈ 100 nN) on areas of 1 μm × 1 μm in order to locally
displace the TOEG6 SAMs and to facilitate the exchange with
the thiolated ssDNA biomolecules (5 μM in TE buﬀer 1 M
NaCl) present in the liquid cell.
Antibody/nanobody conjugate immobilization was per-
formed via DDI,27,28 incubating the ssDNA SAM with Abs/
VHH-F9 at 100 nM in TE buﬀer with 1 M NaCl. ECD-Her2
binding was promoted through the incubation of the antibody/
nanobody nanopatches with a solution containing recombinant
protein at diﬀerent concentrations in PBS buﬀer (binding curve
determination and multiplex measurement) or in Biseko
(detection in standardized human serum).
Topographic height variations of the nanopatches at each
step of the experiment were measured with AFM in gentle
contact mode in liquid using a softer AFM tip (MikroMasch
CSC 38/no Al, spring constant 0.03 nN nm−1), at a cantilever
speed of 1 Hz, in buﬀer solution (TE buﬀer, Tris 10 mM,
EDTA 1 mM). To minimize perturbations, the applied force
during measurement was the minimum stable value (>0.1 nN).
We already proved that under these conditions nanostructures
can be imaged and their height with respect to the SAM carpet
(Δh) can be measured.29 The AFM topography analysis results
were expressed as mean ± SD obtained from measurements
performed on at least four independent patches (n ≥ 4).
The fabrication parameters of the nanografting process were
systematically tuned, consequently modifying the density of
ssDNA molecules adsorbed in the nanopatch.1,8,27 In particular,
it was possible to control the nanoscale DNA surface by
modifying the number of scanning lines during nanografting
over the area, a parameter described by the S/A ratio (where S
is the scanned area and A is the area of the ﬁnal patch).35
Fluorescence Imaging. Fluorescence measurements were
performed both on direct and indirect sandwich conﬁgurations.
Monoclonal IgG antibodies speciﬁc for ECD-Her2 (MGR2,
transtuzumab, and pertuzumab) were directly immobilized via
DDI on the surface, incubating the ssDNA nanopatches with
the immunoconjugate at 100 nM in TE buﬀer 1 M NaCl. ECD-
Her2 binding to immobilized antibodies was obtained by
incubating nanopatches with a solution containing ECD-Her2
at 100 pM (nanoarray validation) or 10 nM (epitope mapping
studies).
With respect to direct measurements, the EM1−GFP fusion
construct (1 μM) was incubated for 1 h over the surface;
indirect measurements were performed using a second Ab
speciﬁc for ECD-Her2 at the saturating concentration of 500
nM and then the secondary ﬂuorescent α-mouse_Alexa488 Ab
(Thermo Fisher Scientiﬁc) diluted 1:500 in PBS buﬀer, which
was incubated over the surface for 30 min. After repeated
washing steps with PBS buﬀer, the gold sample was mounted
on a glass coverslip with Vectashield H-1400 mounting media
(Vector).
Fluorescent images were acquired on an inverted epiﬂuor-
escence microscope (Nikon Eclipse TiU) using 20× (NA =
0.45) and 40× (NA = 0.70) air objectives and a dichroic ﬁlter
for FITC (Nikon; excitation: 465−495 nm; DM: 505 nm;
emission: 515−555 nm). 1600 × 1200 pixel images were
collected using a color digital camera and controller (Nikon
DS-Fi2 and Digital Sight DS-L2) at acquisition times ranging
from 1 to 10 s.
ELISA assay. The indirect ELISA assay was performed ﬁrst
by coating the ECD-Her2 antigen to a PVC microtiter plate.
The protein was diluted to a ﬁnal concentration of 100 μg/mL
in carbonate buﬀer (100 mM, pH 9.6), and 50 μL was used to
coat the wells of the microplate overnight at 4 °C. Then, the
coating solution was removed, and the plate washed three times
with PBS. The coated wells were blocked with 1% BSA in PBS
(blocking buﬀer) for 2 h at room temperature. The plate was
washed twice in PBS, and serial dilutions (from 100 pM to 1
μM) of primary antibody were added. The plate was washed
three times with PBS after a 4 h incubation at 4 °C, and horse
radish peroxidase (HRP)-conjugated secondary antibody
(Sigma) diluted 1:2000 in blocking buﬀer was added. After
the incubation (1 h at 4 °C), binding was assessed by adding
the substrate 3,3′,5,5′-tetramethylbenzidine (TMB, Pierce).
The reaction was stopped with a solution of 1 M HCl after 15
min of incubation at room temperature, and the optical density
was read at 450 nm.
Statistical Analysis. The LoB is the highest measured test
result likely to be observed (typically at 95% certainty) for a
sample containing no analyte. Values above the LoB are not
consistent with the absence of analyte; hence, LoB frequently
replaces the analytical sensitivity of a method. It is calculated as
follows:
= + ×LoB mean 1.645 (SD )blank blank
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